PowerTOST sample size FDA full replicate T/R ratio at 85% [🇷 for BE/BA]

posted by Shuanghe  – Spain, 2016-01-25 18:49 (3807 d 09:16 ago) – Posting: # 15852
Views: 23,410

Hi all,

I just noticed some strange result when I was making sample size plot for FDA full replicate BE using Detlew's famous PowerTOST.

My understanding was that, with T/R ratio fixed (e.g., 90%), when ISCV increase from, say, 10% to 100%, sample size will increase with the increasing ISCV and reach a peak at ISCV=30% then sample size will decrease due to widened BE criteria and after a certain point size will increase again due to high variability. This is true when I tried T/R ratio of 95% or 90%. For example, this plot.

[image]

However, when I was trying T/R ratio of 85% (I know, weird and problematic ratio assumption for BE. Don't ask why. Let's just say that I had to do it), the size peak reached at ISCV=27-28%, not at 30%. See this picture.

[image]


Why is that? Since all other assumptions are same (e.g., T/R ratio is still 85%), when ISCV increased from e.g., 28% to 29% and 30%, shouldn't we need more subjects as the BE criteria is not widened yet?

If my understanding is correct, then maybe it's a bug of the package? If I'm wrong, could anyone explain it in plain English :-D ? Many thanks.


Edit: Category changed. [Helmut]

All the best,
Shuanghe

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
346 visitors (0 registered, 346 guests [including 21 identified bots]).
Forum time: 05:05 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5